Express News | Capricor Therapeutics Inc - Plans to Complete Bla Submission by End of 2024
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) With U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Express News | Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (Bla) With U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Oppenheimer Keeps Their Buy Rating on Capricor Therapeutics (CAPR)